Day: November 5, 2025

NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India image
2 min read

NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India

Pharm'Up
NATCO Pharma Limited announced a major legal victory in its ongoing patent dispute with pharmaceutical giant Roche....
Read More Read more about NATCO Pharma Wins Legal Battle Against Roche to Launch Affordable Risdiplam for Spinal Muscular Atrophy in India
AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing image
2 min read

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

Pharm'Up
AstraZeneca has announced a landmark agreement with President Donald J. Trump’s administration aimed at significantly reducing prescription...
Read More Read more about AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing
Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials image
2 min read

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Pharm'Up
Eli Lilly and Company announced positive topline results from two pivotal Phase 3 trials, ACHIEVE-2 and ACHIEVE-5,...
Read More Read more about Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials
Eli Lilly Partners with Cipla to Launch Second Brand of Tirzepatide (Yurpeak®) for Diabetes and Obesity in India image
2 min read

Eli Lilly Partners with Cipla to Launch Second Brand of Tirzepatide (Yurpeak®) for Diabetes and Obesity in India

Pharm'Up
Eli Lilly and Cipla Limited announced a commercial agreement to distribute and promote tirzepatide in India under...
Read More Read more about Eli Lilly Partners with Cipla to Launch Second Brand of Tirzepatide (Yurpeak®) for Diabetes and Obesity in India
Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions image
2 min read

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Pharm'Up
Biocon Biologics Ltd (BBL), a global biosimilars company, announced that it received a Notice of Compliance (NOC)...
Read More Read more about Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions
Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline image
2 min read

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Pharm'Up
Novartis announced a definitive agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based biopharmaceutical company...
Read More Read more about Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Read These Too

Pharmup 21
2 min read

Understanding Small Intestine Cancer: Risks, Symptoms, and Treatment

Pharm'Up
Pharmup 20
2 min read

Infant Reflux (GER) and GERD: Spitting Up and Growth

Pharm'Up
Pharmup 19
2 min read

Understanding Reflux (GER) and GERD in Children

Pharm'Up
Pharmup 18
2 min read

Gastroenteritis: Understanding the “Stomach Bug” and Food Poisoning

Pharm'Up